N. Verwey

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Niek Verwey, Nicolaas A Verwey, Nicolaas A. Verwey, Niek A Verwey, N. A. Verwey, N A Verwey, Niek A. Verwey, Nicolaas Verwey
Publication record
65 papers · 2,709 citations · H-index 25

PAPERS

Timely diagnosis of dementia: the contribution of non-medical and informal contacts.
20260 citationsauthor #4
From suspicion of cognitive decline to dementia diagnosis: a systematic review of healthcare professionals’ considerations and attitudes
20251 citationsauthor #4
Clinical Manifestations.
20250 citationsauthor #4
Implementation of AD BBMs: Approach in Memory Clinics in the Netherlands
20250 citationsauthor #4
[Frontotemporal dementia in the elderly: Practical tools].
20250 citationsauthor #1
Exploring interdisciplinary perspectives on the implementation of personalized medicine and patient-orchestrated care in Alzheimer's disease: A qualitative study within the ABOARD research project
20250 citationsauthor #6
The impact of tau‐PET in a selected memory clinic cohort: design and rationale of the TAP‐TAU study
20240 citationsauthor #5
Recognition of cognitive dysfunction in hospitalised older patients: a flash mob study
20248 citationsauthor #4
The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study
20243 citationsauthor #5
Cognitive Impairment in the Outpatient Setting: Experiences and Views of Medical Specialists.
20241 citationsauthor #7
Young‐onset dementia in memory clinics in the Netherlands: Study design and description of PRECODE‐GP
20234 citationsauthor #13
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
202227 citationsauthor #18
TAILORED USE OF COMPENSATION STRATEGIES TO ENABLE EXERCISE DESPITE FESTINATION IN PARKINSON’S DISEASE
20210 citationsauthor #2
Neuropathology of Fragile-X associated neuropsychiatric disorders (FXAND)
20200 citationsauthor #3
Neuropathology of FMR1-premutation carriers presenting with dementia and neuropsychiatric symptoms
20208 citationsauthor #3
Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology
202026 citationsauthor #9
P1‐433: DECREASED CSF AMYLOID BETA 38, 40 AND 42 IN GENETICALLY AND PATHOLOGICALLY CONFIRMED FTD
20190 citationsauthor #1
P2-365 ADDED DIAGNOSTIC VALUE OF 18F- FLUTEMETAMOL PET SCANNING IN YOUNG PATIENTS WITH DEMENTIA QUANTIFYING MITOCHONDRIAL AND SYNAPTIC FUNCTION IN ALZHEIMER’S DISEASE USING 18 F]BCPP-EF, [ 11 AND [ 11 C]UCB-J PET IMAGING
20190 citationsauthor #7
P2‐365: ADDED DIAGNOSTIC VALUE OF 18F‐FLUTEMETAMOL PET SCANNING IN YOUNG PATIENTS WITH DEMENTIA
20190 citationsauthor #8
Parkinson Kinetic Graph: Are Motor Fluctuations in Parkinson Disease Related with Disease Duration?
20182 citationsauthor #5
Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
201888 citationsauthor #13
Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study
201642 citationsauthor #5
Cerebrospinal fluid biomarkers of frontotemporal lobar degeneration
20160 citationsauthor #1
Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study
201642 citationsauthor #4
Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
201591 citationsauthor #2
Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study
20157 citationsauthor #5
Cognitive correlates of CSF biomarkers in Frontotemporal dementia
20140 citationsauthor #4
Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
201327 citationsauthor #1
Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia
201321 citationsauthor #4
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
2012298 citationsauthor #3
Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease.
201257 citationsauthor #4
Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers.
201268 citationsauthor #5
Cerebrospinal Fluid β‐Amyloid and Tau Are Not Associated with Risk of Delirium: A Prospective Cohort Study in Older Adults with Hip Fracture
201154 citationsauthor #4
Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
201120 citationsauthor #2
1 Variability in longitudinal CSF Tau and P-Tau measurements
20110 citationsauthor #1
Amyloid- (cid:1) (1– 42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
2010301 citationsauthor #2
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels.
201010 citationsauthor #4
Biochemical markers in dementia:: from mice to men
20105 citationsauthor #1
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
201082 citationsauthor #2
Evaluation of plasma A40 and A42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
20105 citationsauthor #2
Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
201021 citationsauthor #2
Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration.
20108 citationsauthor #2
Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
201087 citationsauthor #2
New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population
201055 citationsauthor #2
Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects
201042 citationsauthor #1
Amyloid- (cid:1) (1– 42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
20095 citationsauthor #2
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease
200980 citationsauthor #5
Biochemical markers for Alzheimer's disease in cerebrospinal fluid
20090 citationsauthor #2
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
2009181 citationsauthor #1
Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding
2009167 citationsauthor #5
CSF biomarker levels in early and late onset Alzheimer's disease.
2009147 citationsauthor #3
Quantification of amyloid-beta 40 in cerebrospinal fluid.
200927 citationsauthor #1
O3‐05‐08: Relationship of cerebrospinal fluid biomarkers with in vivo [11C]PIB and [18F]FDDNP binding
20092 citationsauthor #6
CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
2009116 citationsauthor #2
Contents Vol. 26, 2008
20080 citationsauthor #34
Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
200819 citationsauthor #1
Book review: G.L. Collingridge et al. (eds), Neurobiology of Alzheimer's disease, 3rd edition. New York: Oxford University Press Inc, 2007
20080 citationsauthor #1
1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France
20080 citationsauthor #214
Subject Index Vol. 26, 2008
20080 citationsauthor #34
P3‐099: Serum Amyloid P component as biomarker in Alzheimer's disease
20080 citationsauthor #2
Inflammation Related Factors: Role in Alzheimer’s Disease and Use as Biomarkers
20080 citationsauthor #4
Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease
200843 citationsauthor #1
Test–retest reliability of UPDRS‐III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: An argument against multiple baseline assessments
200468 citationsauthor #3
Assessment of cognition in Parkinson’s disease
2003340 citationsauthor #3
Cerebrospinal Fluid Amyloid-(cid:2) Subtypes in Conﬁrmed Frontotemporal Lobar Degeneration Cases: A Pilot Study
year unknown3 citationsauthor #1

TIMELINE

2003 340 citations

2004 68 citations

2008 62 citations

2009 725 citations

2010 616 citations

2011 74 citations

2012 423 citations

2013 48 citations

2014 0 citations

2015 98 citations

2016 42 citations

2018 90 citations

2019 0 citations

2020 34 citations

2021 0 citations

2022 27 citations

2023 4 citations

2024 12 citations

2025 1 citations

2026 0 citations

Unknown 3 citations

N. Verwey

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT